NDP11033 and SirReal2 also reduced PANC-1 cell viability, suggesting that targeted Sirt2 inhibition via the ‘selectivity pocket’ (Figure 2) may be beneficial in pancreatic cancer [125]. This evidence concerns the gene SIRT2 and pancreatic neoplasm.